Skip to main content
SpringerLink
Log in

Enhancement of tumor cell susceptibility to tumor-infiltrating lymphocytes by cisplatin

  • Original Paper
  • Experimental Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Some means of enhancing the susceptibility of tumor cells to tumor-infiltrating lymphocytes (TIL) are required in adoptive immunotherapy. This study was designed to investigate whether or not tumor cell lysis by TIL was enhanced by treatment of the tumor cells with cisplatin, and also to clarify the mechanism of cisplatin's action on tumor cells. Autologous tumor cells and established cancer cell lines, including KATO-III and MKN-28, were used. Cytotoxic activities of TIL, the surface antigens of tumor cells, conjugation of TIL and tumor cells, and the production of TNFα from TIL were analyzed. Tumor cells treated with 2 μg/ml cisplatin for 12 h in vitro were more susceptible to bulk-cultured TIL and TIL clones. The surface antigens of tumor cells were not altered by the treatment with cisplatin. Cisplatin-treated tumor cells showed a higher binding ratio to TIL than did non-treated tumor cells. The anti-(tumor necrosis factor) (anti-TNF) or anti-TNF receptor antibody blocked the enhancement of cytotoxic activity by cisplatin. Thus, it was clarified that cisplatin enhanced the susceptibility of tumor cells to bulk-cultured TIL and TIL clones. Furthermore, the enhancement of cytotoxic activity by TIL in cisplatin-treated tumor cells was caused by a higher binding ratio to TIL and higher susceptibility to the TNF produced by TIL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

TIL :

tumor-infiltrating lymphocytes

LAK :

lymphokine-activated killer

NK :

natural killer

NC :

naturally cytotoxic

TNF :

tumor necrosis factor

ELISA :

enzyme-linked immunosorbent assay

IL :

interleukin

References

  • Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T (1991) Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 51:1934–1939

    PubMed  Google Scholar 

  • Barth JR, Mule JJ, Asher LA, Sanda GM, Rosenberg, SA (1991) Identification of unique murine tumor associated antigens by tumor-infiltrating lymphocytes using tumor specific secretion of interferon γ and tumor necrosis factor. J Immunol Methods 140:269–279

    PubMed  Google Scholar 

  • Collins JL, Kao MS (1989) The anticancer drug, cisplatin, increase the naturally occurring cell-mediated lysis of tumor cells. Cancer Immunol Immunother 29:17–22

    PubMed  Google Scholar 

  • Eastman A, and Schulte N (1988) Enhanced DNA repair as a mechanism of resistance tocis-diammine-dichloroplatinum (II). Biochemistry 27:4730–4734

    PubMed  Google Scholar 

  • Fawcett J, Holness CL, Needham LA, Turley H, Gatter KC, Mason DY, Simmonds DL (1992) Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature 360:481–484

    PubMed  Google Scholar 

  • Itoh K, Hayakawa K, Salmeron MA, Legha SS, Murray JL, Talpaz M, Balch CM, Parkinson DR, Lee K, Zukiwaski A A, Ring SE, Lapushin R, Augustus LB (1991) Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. Cancer Immunol Immunother 33:238–246

    PubMed  Google Scholar 

  • Iwahashi M, Tanimura H, Yamaue H, Tsunoda T, Tani M, Tamai M, Noguti K, Hotta T (1992) Defective autologous mixed lymphocyte reaction (AMLR) and killer activity generated in the AMLR in cancer patients. Int J Cancer 51:67–71

    PubMed  Google Scholar 

  • Kradin RL, Kurnick JT, Lazarus DS, Pleffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ, Strauss HM (1989) Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 8638:577–580

    Google Scholar 

  • Mizutani Y, Bonavida B, Nio Y, Yoshida O (1993) Enhanced susceptibility ofcis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer 71:1313–1321

    PubMed  Google Scholar 

  • Nakamura T, Takahashi K, Koyanagi M, Yagita H, Okumura K (1991) Activation of a natural killer clone upon target cell binding via CD2. Eur J Immunol 21:831–834

    PubMed  Google Scholar 

  • Rivoltini I L, Cattoretti A G, Arienti F, Mastroianni A, Melani C, Colombo MP, Parmiani G (1991) The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin associated with a high expression of ICAM-1, LFA-3, NCA and less-differentiated phenotype. Int J Cancer 47:746–754

    PubMed  Google Scholar 

  • Rosenberg B, Van CL, and Krigas T (1965) Inhibition of cell division inEscherichia coli by electrolysis products from a platinum electrode. Nature 205:698–699

    PubMed  Google Scholar 

  • Rosenberg SA, Sepiess P, Latreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318–1321

    PubMed  Google Scholar 

  • Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JG, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676–1680

    PubMed  Google Scholar 

  • Rothlein R, Dustin ML, Marlin SD, Springer TA (1986) A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 137:1270–1274

    PubMed  Google Scholar 

  • Springer TA, Davignon D, Ho MK, Kurzinger K, Martz E, Sancher-Madrid F (1982) LFA-1 and Lyt-2,3, molecules associated with T-lymphocyte mediated killing; and Mac-1 an LFA-1 homologue associated with complement receptor function. Immunol Rev 68:111–135

    Google Scholar 

  • Stauton DE, Dustin ML, Springer TA (1989) Functional cloning of ICAM-2, cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 339:61–64

    PubMed  Google Scholar 

  • Tsunoda T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Noguchi K, Hotta T, Mizobata S, Arii K (1996) Clonal and functional analysis for the augmentation of tumour-infiltrating lymphocytes by interleukin 4. Br J Cancer 74:1085–1089

    PubMed  Google Scholar 

  • Wacholtz MC, Patel SS, Lipsky PE (1989) Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J Exp Med 170:431–436

    PubMed  Google Scholar 

  • Yamaue H, Tanimura H, Tsunoda T, Iwahashi M, Tani M, Tamai M, Inoue M (1990) Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes. Biotherapy 4:473–477

    Google Scholar 

  • Yamaue H, Tanimura H, Nogushi K, Iwahashi M, Tsunoda T, Tani M, Tamai M, Hotta T, Mizobata S, Arii K (1991) Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells. J Clin Lab Immunol 35:165–170

    PubMed  Google Scholar 

  • Yamaue H, Tanimura H, Noguchi K, Hotta T, Tani M, Tsunoda T, Iwahashi M, Tamai M, Iwakura S (1992a) Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using MTT assay. Br J Cancer 66:794–799

    PubMed  Google Scholar 

  • Yamaue H, Tanimura H, Tsumoda T, Iwahashi M, Tani M, Tamai M, Noguti K, Hotta T, Arii K (1992b) Enhancement of tumor cell susceptibility to lymphokine-activated killer cells by treatment with the streptococcal preparation OK432. Biotherapy 5:83–93

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Second Department of Surgery, Wakayama Medical School, 27-Shichibancho, 640, Wakayama, Japan

    Kohei Noguchi, Hiroshi Tanimura, Hiroki Yamaue, Makoto Iwahashi, Takuya Tsunoda, Masaji Tani, Mikiko Tamai, Tsukasa Hotta, Shizuma Mizobata & Kazuo Arii

Authors
  1. Kohei Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Tanimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroki Yamaue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Makoto Iwahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuya Tsunoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masaji Tani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mikiko Tamai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tsukasa Hotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shizuma Mizobata
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazuo Arii
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Noguchi, K., Tanimura, H., Yamaue, H. et al. Enhancement of tumor cell susceptibility to tumor-infiltrating lymphocytes by cisplatin. J Cancer Res Clin Oncol 123, 345–351 (1997). https://doi.org/10.1007/BF01438311

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01438311

Key words

Search

Navigation